© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Based on recent data, Dermata Therapeutics, Inc. (DRMA) shows an Average True Range (ATR) of 0.25 and an Enterprise Value of -5.06M. Its average trading volume over the past 3 months is 149.99K, indicating liquidity. These fundamental metrics provide insight into DRMA's underlying financial health and market activity.
Dermata Therapeutics, Inc. (DRMA) technical indicators as of December 24, 2025: the SMA 20 is -23.06%, SMA 50 at -34.6%, and SMA 200 at -67.3%. The RSI 14 value is 29.54, suggesting its current momentum. These technical analysis signals help assess DRMA's price trends and potential future movements.
Dermata Therapeutics, Inc. (DRMA) stock performance overview as of December 24, 2025: The 52-week high is $63.33 (currently -91.39% below), and the 52-week low is $0.574 (currently -4.23% above). Over the past year, DRMA's performance is 85.45%, compared to the S&P 500's 9.35% change.
According to market data, Dermata Therapeutics, Inc. (DRMA) stock's recent performance metrics show that over the last month, DRMA is -18.4%, with a Year-to-Date (YTD) performance of 51.11%. Over the past year, the stock has seen a 85.45% change. These figures summarize DRMA's price movements across various periods, reflecting its historical returns.
According to current financial data, DRMA stock's P/E (TTM) ratio is -0.23, which compares to the S&P 500's P/E of 32.59. The sector median P/E is -1.24. Key valuation ratios for DRMA, including P/S (N/A), P/B (0.52), and P/FCF (-0.15), offer insights into how the company is valued relative to its earnings, sales, book value, and free cash flow.